drugset / Trial / NCT00813137
FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
Phase 2
Unknown
120 enrolled
Simcere Pharmaceutical Co., Ltd
The Affiliated Changzhou Tumor Hospital of Suzhou University · collab
NaSingle-groupOpen-labelTreatment
Summary
FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonged the overall survival, time to progression and improved response rate in metastatic lung cancer in a large phase III clinical trial in china, so we design this trial to evaluate the safty and efficacy of FolFox4 plus Endostar in patients with advanced colorectal cancer
Timeline
- Start
- 2008-10
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 200 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 600 mg/m2 | Intravenous |